ADA/EASD糖尿病高血糖管理声明

2012-04-25 沐雨译 医学论坛网

  2型糖尿病的血糖管理已日趋复杂并伴随争议,随着可用药物的不断增多,有关药物潜在不良反应的担忧及强化血糖控制对于大血管并发症益处的不确定性不断增加。很多医生在为患者制定最佳策略时感到困惑。   为此,美国糖尿病学会(ADA)和欧洲糖尿病研究学会(EASD)召集了一个联合工作组,检验了证据并提出了非妊娠成人2型糖尿病患者降糖治疗的建议。ADA和EASD及其他学会和组织已经发布过几个相关的指南文件

  2型糖尿病的血糖管理已日趋复杂并伴随争议,随着可用药物的不断增多,有关药物潜在不良反应的担忧及强化血糖控制对于大血管并发症益处的不确定性不断增加。很多医生在为患者制定最佳策略时感到困惑。

  为此,美国糖尿病学会(ADA)和欧洲糖尿病研究学会(EASD)召集了一个联合工作组,检验了证据并提出了非妊娠成人2型糖尿病患者降糖治疗的建议。ADA和EASD及其他学会和组织已经发布过几个相关的指南文件,但由于血糖控制的获益/风险相关信息、近期证据涉及到几种新药的疗效和安全性、有些药物的撤出或限制,以及以患者为中心的护理的需求,指南需要进行更新。

  本声明纳入了最新的证据、经验和观点,文件特指血糖控制,但这显然应在多重危险因素减少的整体框架内推动。2型糖尿病患者心血管发病率和死亡率危险升高,强化干预心血管危险因素(降压、降脂、抗血小板治疗、戒烟)会有更多益处。

  本声明4月19日在线发表与《糖尿病护理》杂志。

  链接:

 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. 

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Apr 19.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690558, encodeId=149b16905583c, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Feb 17 20:16:00 CST 2013, time=2013-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261045, encodeId=ba1a126104576, content=<a href='/topic/show?id=30c6102e2607' target=_blank style='color:#2F92EE;'>#高血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102726, encryptionId=30c6102e2607, topicName=高血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264439, encodeId=f34c126443954, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521555, encodeId=6a991521555a6, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534052, encodeId=47a0153405291, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2013-02-17 okhuali
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690558, encodeId=149b16905583c, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Feb 17 20:16:00 CST 2013, time=2013-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261045, encodeId=ba1a126104576, content=<a href='/topic/show?id=30c6102e2607' target=_blank style='color:#2F92EE;'>#高血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102726, encryptionId=30c6102e2607, topicName=高血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264439, encodeId=f34c126443954, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521555, encodeId=6a991521555a6, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534052, encodeId=47a0153405291, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690558, encodeId=149b16905583c, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Feb 17 20:16:00 CST 2013, time=2013-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261045, encodeId=ba1a126104576, content=<a href='/topic/show?id=30c6102e2607' target=_blank style='color:#2F92EE;'>#高血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102726, encryptionId=30c6102e2607, topicName=高血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264439, encodeId=f34c126443954, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521555, encodeId=6a991521555a6, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534052, encodeId=47a0153405291, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 般若傻瓜
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690558, encodeId=149b16905583c, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Feb 17 20:16:00 CST 2013, time=2013-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261045, encodeId=ba1a126104576, content=<a href='/topic/show?id=30c6102e2607' target=_blank style='color:#2F92EE;'>#高血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102726, encryptionId=30c6102e2607, topicName=高血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264439, encodeId=f34c126443954, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521555, encodeId=6a991521555a6, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534052, encodeId=47a0153405291, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690558, encodeId=149b16905583c, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Feb 17 20:16:00 CST 2013, time=2013-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261045, encodeId=ba1a126104576, content=<a href='/topic/show?id=30c6102e2607' target=_blank style='color:#2F92EE;'>#高血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102726, encryptionId=30c6102e2607, topicName=高血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264439, encodeId=f34c126443954, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521555, encodeId=6a991521555a6, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534052, encodeId=47a0153405291, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 qilu_qi

相关资讯

Diabetes Care:终末糖基化产物(AGE)水平升高与视网膜病变进展相关

  美国学者的一项研究表明,在1型糖尿病患者中,免疫复合物中(IC)中终末糖基化产物(AGE)-LDL和氧化LDL(oxLDL)水平升高与晚期视网膜病变进展风险升高相关。论文于2011年4月17日在线发表于《糖尿病护理》(Diabetes Care)杂志。   此项研究共纳入517例糖尿病患者,并测定了IC中的AGE-LDL和oxLDL水平。利用立体眼底摄像评估视网膜病变。利用Cox比

Diabetes Care:高胰岛素正糖钳夹早期预测胰岛素抵抗

  美国学者的一项研究建立了通过高胰岛素正糖钳夹确定胰岛素抵抗的切点,同时也提供了通过常规测定临床和生化标志物预测胰岛素抵抗的分类树。该研究使钳夹技术从研究工具拓展到能够为研究受试者提供具有临床意义的信息,并且具有早期识别胰岛素抵抗的潜力。论文于2011年4月17日在线发表于《糖尿病护理》(Diabetes Care)杂志。   此项研究旨在为从高胰岛素正糖钳夹研究中确认胰岛素抵抗的分

PNAS:德国科学家揭示甘草具有抗糖尿病的作用

甘草是传统中医中的一种很重要的草本植物,其使用种类记载已久。数千年来,中国医疗家们使用甘草来治疗多种疾病,上至喉咙痛,下至溃疡,而且还被当做养心和补脾的滋补品。其根也被用于药用上。近年来自世界的研究机构及许多科学家对于甘草研究均表现出浓厚的兴趣。有研究证实甘草根作为甘草果糖原材料,可舒缓减轻胃及呼吸道疾患。 近日来自德国柏林马克斯-普朗克分子遗传学研究所的研究人员发现甘草根(liquorice

肥胖糖尿病患者减肥手术表现优于药物治疗

  《外科学文献》(Arch Surg)4月16日在线发布的一项研究表明,在病态肥胖的糖尿病患者中,腹腔镜胃束带减肥术较药物治疗对控制糖尿病更有效。   研究者对60例患者随访了18个月,其中半数进行手术,其余皆是最佳药物治疗。治疗前,患者的平均体质指数(BMI)约为40。第18个月,手术患者体质减轻较药物治疗患者多,最终BMI分别为28和40。80%的手术患者糖尿病痊愈,而药物

中国高血压患者合并糖尿病较常见

  我国北京安贞医院研究人员在2012年世界心脏病学大会(4月18~21日,阿联酋迪拜)上公布的一项研究显示:虽然我国高血压患者的糖尿病流行率较高,但是,即便他们正在接受糖尿病治疗,其糖尿病知晓率仍很低。此外,高血压合并糖尿病的患者的降血糖治疗率和血糖达标率均很低。研究人员认为:在接受治疗的中国高血压患者中,强调血糖检测的重要性和提高护理质量很重要。   此项横断面调查样本来自2009年中

刘学波:糖尿病合并冠心病 介入治疗重在管理

       导语:糖尿病与心血管病之间存在着密切的内在联系,二者互为高危人群。2001年美国国家胆固醇教育计划成人治疗指南Ⅲ(NCEP-ATP Ⅲ)指出:糖尿病是冠心病的等危症。2007年,美国心脏病学院甚至发出了“糖尿病就是心血管病”的呼声。提高对糖尿病患者冠状动脉病变和介入治疗的认识,以及加强经皮冠状动脉介入治疗(PCI)术后对血糖等危险因素的管理,对